Inhibitor Therapeutics, Inc.

Equities

INTI

US45720M1053

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 09:39:44 2024-04-24 am EDT			5-day change	1st Jan Change
0.0858 ^USD	+50.53%		+25.26%	-6.74%

Mar. 29	Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Introducing Inhibitor Therapeutics, Inc. Announces Scientific Advisory Board	CI

Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 12, 2022 at 04:18 pm EDT

Inhibitor Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 0.077567 million compared to USD 0.066182 million a year ago.
For the six months, net loss was USD 0.176477 million compared to USD 0.19402 million a year ago.

Latest news about Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Introducing Inhibitor Therapeutics, Inc. Announces Scientific Advisory Board	Dec. 19	CI
Inhibitor Therapeutics, Inc. Announces the Use of Itraconazole to Treat Basal Cell Carcinoma Nevus Syndrome	Dec. 19	CI
Inhibitor Therapeutics, Inc. Enters into an Exclusive, Worldwide Licensing Agreement with Johns Hopkins University	Dec. 14	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Inhibitor Therapeutics, Inc. Appoints Michelle Yanez as an Independent Director and a Member of the Audit Committee	23-10-18	CI
Inhibitor Therapeutics, Inc. Appoints Ronald E. Osman as Non-Independent Director on the Board	23-08-29	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Inhibitor Therapeutics, Inc. Announces Board Changes	23-05-31	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Inhibitor Therapeutics, Inc. Announces Retirement of Debra Peattie from the Board of Directors	22-06-03	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
Inhibitor Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-03-29	CI
Inhibitor Therapeutics, Inc. Executes A Letter Agreement with Mayne Pharma to Amend the Loan Agreement and the Facility	22-01-18	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-13	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-26	CI
Inhibitor Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	21-03-25	CI
Inhibitor Therapeutics, Inc. and Mayne Pharma Ventures Pty Ltd Enters Into Loan Agreement	20-12-17	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-16	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-12	CI

Chart Inhibitor Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Inhibitor Therapeutics, Inc. is a pharmaceutical development company. The Company is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the United States utilizing itraconazole, a drug approved by the United States Food and Drug Administration (FDA) to treat fungal infections. The Company has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. The Company's intellectual property in the form of issued United States patents includes treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, and treatment of lung cancer using hedgehog pathway inhibitors.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INHIBITOR THERAPEUTICS, INC.	-6.74%	14.76M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.22%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.84%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs